Combined Use of Niraparib Enhanced the Inhibitory Effect of Anti-GD2 Antibody on Osteosarcoma Cells

Abstract Purpose To study the inhibitory effect of Niraparib in combination with Anti-GD2 Antibody on Osteosarcoma. Methods The migration ability of OS cells was detected by scratch test. Transwell experiment and CCK8 assay were used to detect the invasion and proliferation. WB was used to detect BALP and CICP protein expression. The mRNA expression of BALP and CICP was detected by QRT-PCR. Results Scratch test showed that the distance between cells in Niraparib + GD2 group was 1.07 ± 0.04 and 1.06 ± 0.04 at 48h, both p < 0.05, and the differences were statistically significant. Transwell experiment showed that the number of invasive cells was 21 ± 1.5 in Niraparib + GD2 group, p < 0.05, and the differences were statistically significant. CCK8 assay showed that the absorbance of Niraparib + GD2 group was 0.16 ± 0.10 on day 5, p < 0.05, and the differences were statistically significant. WB showed that compared with the Control group, the semi-quantitative results of BALP expression in Niraparib + GD2 group were 0.751 ± 0.135 and CICP expression were 1.086 ± 0.115, both p < 0.05, and the differences were statistically significant. QRT-PCR showed that the absorbance of Niraparib + GD2 group was 0.173 ± 0.065 and 0.170 ± 0.078 on day 14, both p < 0.01, and the differences were statistically significant. Conclusion Niraparib combined with Anti-GD2 Antibody has a more prominent inhibitory effect on OS.